Company intelligence / Profile preview

DxNow

Gaithersburg, Maryland, United States

Ownership: Private
Employees: ~6
Development stage: Other

Overview

DxNow received FDA 510(k) clearance in March 2018[3] for its ZyMōt ICSI and ZyMōt Multi sperm separation devices. The devices are designed to simulate the cervical and uterine pathway, facilitating separation and preparation of highly-motile sperm with normal morphology for use in assisted reproductive technology (ART) procedures including intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and in vitro fertilization (IVF)[4]. The ZyMōt devices were the first of their kind cleared in the U.S. market[3].

Therapeutic areas: HematologyNephrologyOtherWomen's HealthInfectious DiseasesOncology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Exclusive licensee of Brigham & Women's Hospital and Stanford School of Medicine patents[1]

Beyond the preview

Go deeper on DxNow.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DxNow.

Explore the full profile